VivoSeq
Infectious Disease

Visceral Leishmaniasis

20

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Visceral Leishmaniasis is an emerging landscape with 20 programs across 8 companies. The most active players are GSK, Novartis, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 6 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 2Novartis logo

Novartis

2 programs

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3K

Knight Therapeutics (USA) Inc

1 program

Phase 3O

Oncozyme Pharma Inc.

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Approved

Pipeline

Programs by Phase

Preclinical4

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

N-Acetylcysteine

Novartis

Pentavalent Antimonial

Hospital Universitário Professor Edgard Santos

Amphotericin B Fat Emulsion

Banaras Hindu University

Phase 1
No programs
Phase 24

SCH708980 Anti-IL-10 Monoclonal

National Institute of Allergy and Infectious Diseases (NIAID)

LXE408

Novartis

Sodium Stibogluconate

Drugs for Neglected Diseases

Sitamaquine

GSK

Phase 36

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Miltefosine

Knight Therapeutics (USA) Inc

Pentamidine

Oncozyme Pharma Inc.

Paromomycin

Drugs for Neglected Diseases

Miltefosine and Paromomycin

Drugs for Neglected Diseases

Approved6

Ambisome

Gilead

Meglumine Antimoniate

University of Brasilia

Amphotericin B Deoxycholate

Merck & Co.

Mitefosine

International Centre for Diarrhoeal Disease Research, Bangladesh

Paromomycin Sulfate

PATH

Analysis

Trial Status

24

clinical trials

Completed17 · 71%
Active, not recruiting2 · 8%
Terminated2 · 8%
Unknown status2 · 8%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

24 trials

A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Active, not recruiting·UUniversity of York·N/A·NCT04342715·216 enrolled
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
Active, not recruiting·DDrugs for Neglected Diseases·Phase 2·NCT05593666·101 enrolled
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
Completed·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 4·NCT01975051·36 enrolled
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
Completed·UUniversity of Brasilia·Phase 4·NCT01032187·101 enrolled
Combination Therapy in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00523965·624 enrolled
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Completed·PPATH·Phase 3·NCT00216346·667 enrolled
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
Completed·DDrugs for Neglected Diseases·Phase 2·NCT05957978·52 enrolled
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00628719·400 enrolled
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
Completed·—·Phase 3·NCT00629031·329 enrolled
A Community Trial for Visceral Leishmaniasis (VL)
Completed·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·N/A·NCT01069198·200 enrolled
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
Completed·GSK logoGSK·Phase 2·NCT00381394·61 enrolled
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
Completed·DDrugs for Neglected Diseases·Phase 3·NCT00696969·634 enrolled
Amphotericin B Treatment in Visceral Leishmaniasis
Completed·—·N/A·NCT00310505·1,500 enrolled
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
Completed·PPATH·N/A·NCT01328457·120 enrolled
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
Completed·DDrugs for Neglected Diseases·Phase 2·NCT02431143·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)